Middle East and Africa Stem Cell Therapy Market Introduction and Overview
According to SPER Market Research, the Middle East and Africa Stem Cell Therapy Market is estimated to reach USD 158.57 million by 2033 with a CAGR of 10.53%.
The report includes an in-depth analysis of the Middle East and Africa Stem Cell Therapy Market, including market size and trends, product mix, applications, and supplier analysis. Stem cell therapy, also known as regenerative medicine, uses stem cells or their derivatives to promote the repair of sick, dysfunctional, or wounded tissue. It is the next step in organ transplantation, using cells rather than donor organs, which are in short supply. Stem cells are cells that have the capacity to differentiate into a variety of cell types in the body. These act as a mending system for the body. Adult stem cells and embryonic stem cells are the two different kinds of stem cells. Stem cells are split into two types: pluripotent and multipotent. Pluripotent stem cells are replicating cells that originate in the embryo or foetal organs.
- Pluristem Inc. declared in March 2022 that the phase I clinical trials for PLX-R18 were successful. In order to treat graft failure, incomplete haematopoietic recovery after haemodialysis (HCT), and to prevent and treat acute radiation syndrome (ARS), the U.S. Food and Drug Administration (FDA) granted orphan drug status. The market participant would be eligible to perform Phase II and III clinical trials and get post-marketing approval if the phase I clinical trials were successfully completed.
Market Opportunities and Challenges
Opportunities-
Increased frequency and incidence of chronic diseases: Chronic diseases are widespread health issues around the world. In the Middle East and Africa, one out of every three adults has a chronic ailment. Chronic diseases have harmed the health and quality of life of many citizens. Chronic diseases, such as cancer, musculoskeletal disorders, neurological disorders, chronic injuries, cardiovascular and gastrointestinal problems, can result in hospitalisation, long-term incapacity, a lower quality of life, and death. Mesenchymal stem cells can penetrate and integrate into many organs, heal cardiovascular, lung, and spinal cord injuries, and enhance the condition of autoimmune, liver, and bone and cartilage illnesses. Stem cells are an effective treatment for disorders characterised by inflammation, immune system dysfunction, and/or tissue deterioration.
Challenges-
The growing expense of research on stem-cell-based therapies: A cutting-edge and innovative treatment option for a number of diseases is stem cell therapy. For a number of illnesses, the expense of the therapy can occasionally be a worry. The insurance industry and the general public have not embraced the stem cell area, which is currently very specialised. Medical insurance does not pay the expense of research therapy based on stem cells. Patients are forced to bear these expenses. It is therefore anticipated that the current high cost will trend downward.
Market Competitive Landscape
The competitive landscape of the Middle East and Africa stem cell therapy market includes information from competitors. The company overview, financials, revenue generated, market potential, investment in R&D, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, are all included. Some of the market's top participants are U.S. Stem Cell, Inc, STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc, NuVasive, Inc, Mesoblast Limited, Athersys, Inc, Takeda Pharmaceutical Company Limited, Medipost Co., Ltd, JCR Pharmaceuticals Co., Ltd, Pharmicell Co., Ltd, Hope Biosciences, BrainStorm Cell Therapeutics Inc.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product Type, By Type, By Application, By End User, By Distribution Channel
|
| Regions covered | South Africa, Egypt, United Arab Emirates, Rest of Middle East and Africa.
|
| Companies Covered | U.S. Stem Cell, Inc, STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc, NuVasive, Inc, Mesoblast Limited, Athersys, Inc, Takeda Pharmaceutical Company Limited, Medipost Co., Ltd, JCR Pharmaceuticals Co., Ltd, Pharmicell Co., Ltd, Hope Biosciences, BrainStorm Cell Therapeutics Inc.
|
COVID-19 Impact on Middle East and Africa Stem Cell Therapy Market
The healthcare sector, particularly the market for stem cell therapy in the MEA region, has been significantly impacted by the COVID-19 epidemic. The pandemic disrupted clinical trials and healthcare systems, but it also brought attention to the possibility of regenerative therapy in treating COVID-19 long-term consequences like organ damage and immune system malfunction. The COVID-19 pandemic has spurred research into stem cell therapy and raised awareness of the need for novel treatments for respiratory ailments and other COVID-19-related side effects.
Key Target Audience:
- Stem Cell Therapy Providers
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Regulatory Bodies and Government Agencies
- Investors and Venture Capitalists
- Medical Device Manufacturers
- Healthcare Professionals (Doctors, Surgeons, and Specialists)
- Patients and Patient Advocacy Groups
- Insurance Companies and Healthcare Payers
Our in-depth analysis of the Middle East and Africa Stem Cell Therapy Market includes the following segments:
|
By Product Type:
|
Bone Marrow Derived Mesenchymal Stem Cells
Placental or Umbilical Stem Cell
Adipose Tissue Derived Mesenchymal Stem Cells
Others
|
|
By Type:
|
Allogeneic Stem Cell Therapy
Autologous Stem Cell Therapy
|
|
By Application:
|
Musculoskeletal Disorders
Wounds and Injuries
Acute Graft-Versus-Host Disease (AGVHD)
Surgeries
Gastrointestinal Diseases
Cardiovascular Diseases
Others
|
|
By End User:
|
Hospitals and Surgical Centers
Therapeutic Companies
Services Companies
Others
|
|
By Distribution Channel:
|
Direct Tenders
Third Party Distributors
|
Key Topics Covered in the Report:
- Middle East and Africa Stem Cell Therapy Market Size (FY’2024-FY’2033)
- Overview of Middle East and Africa Stem Cell Therapy Market
- Segmentation of Middle East and Africa Stem Cell Therapy Market by Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others)
- Segmentation of Middle East and Africa Stem Cell Therapy Market by Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy)
- Segmentation of Middle East and Africa Stem Cell Therapy Market by Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease, Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others)
- Segmentation of Middle East and Africa Stem Cell Therapy Market by End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others)
- Segmentation of Middle East and Africa Stem Cell Therapy Market by Distribution Channel (Direct Tender, Third Party Distributors)
- Statistical Snap of Middle East and Africa Stem Cell Therapy Market
- Expansion Analysis of Middle East and Africa Stem Cell Therapy Market
- Problems and Obstacles in Middle East and Africa Stem Cell Therapy Market
- Competitive Landscape in the Middle East and Africa Stem Cell Therapy Market
- Impact of COVID-19 and Demonetization on Middle East and Africa Stem Cell Therapy Market
- Details on Current Investment in Middle East and Africa Stem Cell Therapy Market
- Competitive Analysis of Middle East and Africa Stem Cell Therapy Market
- Prominent Players in the Middle East and Africa Stem Cell Therapy Market
- SWOT Analysis of Middle East and Africa Stem Cell Therapy Market
- Middle East and Africa Stem Cell Therapy Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Middle East and Africa Stem Cell Therapy Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Middle East and Africa Stem Cell Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Middle East and Africa Stem Cell Therapy Market
7. Middle East and Africa Stem Cell Therapy Market, By Product Type (USD Million) 2020-2033
7.1. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Product Type, 2020-2026
7.2. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Product Type, 2027-2033
7.3. Bone Marrow Derived Mesenchymal Stem Cells
7.4. Placental or Umbilical Stem Cell
7.5. Adipose Tissue Derived Mesenchymal Stem Cells
7.6. Others
8. Middle East and Africa Stem Cell Therapy Market, By Type (USD Million) 2020-2033
8.1. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Type, 2020-2026
8.2. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Type, 2027-2033
8.3. Allogeneic Stem Cell Therapy
8.4. Autologous Stem Cell Therapy
9. Middle East and Africa Stem Cell Therapy Market, By Application (USD Million) 2020-2033
9.1. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Application, 2020-2026
9.2. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Application, 2027-2033
9.3. Musculoskeletal Disorders
9.4. Wounds and Injuries
9.5. Acute Graft-Versus-Host Disease (AGVHD)
9.6. Surgeries
9.7. Gastrointestinal Diseases
9.8. Cardiovascular Diseases
9.9. Others
10. Middle East and Africa Stem Cell Therapy Market, By End User (USD Million) 2020-2033
10.1. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By End User, 2020-2026
10.2. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By End User, 2027-2033
10.3. Hospitals and Surgical Centers
10.4. Therapeutic Companies
10.5. Services Companies
10.6. Others
11. Middle East and Africa Stem Cell Therapy Market, By Distribution Channel (USD Million) 2020-2033
11.1. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Distribution Channel, 2020-2026
11.2. Middle East and Africa Stem Cell Therapy Market Size, Share and Forecast, By Distribution Channel, 2027-2033
11.3. Direct Tenders
11.4. Third Party Distributors
12. Middle East and Africa Stem Cell Therapy Market Forecast, 2020-2033 (USD Million)
12.1. Middle East and Africa Stem Cell Therapy Market Size and Market Share
13. Middle East and Africa Stem Cell Therapy Market, By Region, 2020-2033 (USD Million)
13.1. Middle East and Africa Stem Cell Therapy Market Size and Market Share By Region (2020-2026)
13.2. Middle East and Africa Stem Cell Therapy Market Size and Market Share By Region (2027-2033)
13.3. South Africa
13.4. Egypt
13.5. United Arab Emirates
13.6. Rest of Middle East and Africa
14. Company Profile
14.1. U.S. Stem Cell, Inc
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. STEMPEUTICS RESEARCH PVT LTD
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Pluristem Inc
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. NuVasive, Inc
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Mesoblast Limited
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Athersys, Inc
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Takeda Pharmaceutical Company Limited
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Medipost Co., Ltd
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. JCR Pharmaceuticals Co., Ltd
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Pharmicell Co., Ltd
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Hope Biosciences
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments
14.12. BrainStorm Cell Therapeutics Inc
14.12.1. Company details
14.12.2. Financial outlook
14.12.3. Product summary
14.12.4. Recent developments
14.13. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links